CliniBioLab Chemin Clément
ActiveSummary
CliniBioLab Chemin Clément has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €66,000 and a net result of €66,840. The computed 12-month bankruptcy probability is 0.6% (low).
Overview
Official details
Source: KBO- Status
- Active since 30-09-2024 Normal situation
- Activity
- “Toutes opérations se rapportant directement ou indirectement à l’analyse médicale, la biologie clinique, la…” (deed in French)From the articles, 9 activitiesNo NACE code in the KBO yet
- Establishment unit
- 2.365.150.901 1050 Elsene, since 30-09-2024
- Financial year end
- 30 June
- Peppol
- Reachable since 10-11-2025
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.6%
- Gross margin
- €88,735
- Turnover
- ≈ €270,000
- estimated
- Profit
- €66,840
- Equity
- €66,000
- Total assets
- €88,629
Score breakdownraises riskFounded in 2024No main activity registeredlowers riskLiquidity: current ratio 3.81, cash €43,208Equity €66,000 (74.5% of total assets)Show the evidence
Checked score
About 6 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (no NACE code, micro). It does better than 62% of them on solvency, 81% on liquidity and 90% on profitability.
The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Searched, nothing found (1)
Recent changes
- · Gazette deed IncorporationAppointment: Clément Michel CHEMIN (statutory director)
Key facts about CliniBioLab Chemin Clément
- What is the company number of CliniBioLab Chemin Clément?
- The company number of CliniBioLab Chemin Clément is 1014.381.557. The VAT number is the same number with BE in front: BE 1014.381.557.
- Where is CliniBioLab Chemin Clément based?
- The registered office is at de Stassartstraat 127, 1050 Elsene.Company details
- What is the legal form of CliniBioLab Chemin Clément?
- The legal form of CliniBioLab Chemin Clément is Private limited company (BV).
- When was CliniBioLab Chemin Clément founded?
- CliniBioLab Chemin Clément was founded on 30-09-2024.
- Is CliniBioLab Chemin Clément still active?
- Yes, CliniBioLab Chemin Clément is an active enterprise in the KBO register.
- What is the turnover of CliniBioLab Chemin Clément?
- The turnover in financial year 2025 is ≈ €270,000. This figure is estimated from the gross margin of €88,735 and 2,672 comparable companies of the same size. It probably lies between €180,000 and €460,000. It is a rough estimate.Financials
- Is CliniBioLab Chemin Clément profitable?
- In financial year 2025, CliniBioLab Chemin Clément made a profit of €66,840.
- Where can I find the annual accounts of CliniBioLab Chemin Clément?
- CliniBioLab Chemin Clément filed 1 annual account with the National Bank of Belgium, for financial year 2025.
Next steps
See how customers, suppliers and banks see your own company and what to improve first.